ImmunityBio, Inc. (IBRX) shares surged 5.19% in pre-market trading on Tuesday, showing significant investor interest ahead of the regular session.
The sharp rise appears to be driven by positive analyst sentiment, with HC Wainwright & Co. maintaining its Buy rating on the biopharmaceutical company. Analyst ratings often serve as key catalysts for stock movements, particularly when established firms reaffirm bullish positions on companies.